Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zileuton. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 known ✓ | P09917 | 6/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | PTGES | O14684 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | LTA4H | P09960 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 1/20 | 1.00 |
| ▸ | ALOX5AP | P20292 | 1/20 | 1.00 |
| ▸ | LOX | P28300 | 1/20 | 1.00 |
| ▸ | EPHX2 | P34913 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | LTB4R | Q15722 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zileuton SCHEMBL8876686 | 1.00 | ALOX5 (1.00) | ALOX5CYP1A2PTGESLMNALTA4H | |
| Zileuton SCHEMBL6601944 | 1.00 | ALOX5 (1.00) | ALOX5CYP1A2PTGESLMNALTA4H | |
| Zileuton SCHEMBL18251470 | 1.00 | ALOX5 (1.00) | ALOX5CYP1A2PTGESLMNALTA4H | |
| Zileuton SCHEMBL126156 | 1.00 | ALOX5 (1.00) | ALOX5CYP1A2PTGESLMNALTA4H | |
| Zileuton SCHEMBL28562765 | 0.99 | ALOX5 (0.97) | ALOX5CYP1A2PTGESLMNALTA4H | |
| Zileuton SCHEMBL9602587 | 0.99 | ALOX5 (0.97) | ALOX5CYP1A2PTGESLMNALTA4H | |
| Zileuton SCHEMBL6335013 | 0.99 | ALOX5 (0.97) | ALOX5CYP1A2PTGESLMNALTA4H | |
| Zileuton SCHEMBL20770716 | 0.95 | ALOX5 (0.90) | ALOX5CYP1A2PTGESLMNALTA4H | |
| Methylamine SCHEMBL9601432 | 0.87 | ALOX5 (0.77) | ALOX5CYP1A2PTGESLMNALTA4H | |
| SCHEMBL1444813 | 0.87 | ALOX5 (0.76) | ALOX5CYP1A2PTGESLMNALTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 22752 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6436924-B1 | — | — | None | — | — | US | claimed |
| EP-4739297-A1 | MODULATORS OF LYPOXYGENASES FOR TREATING CONDITIONS ASSOCIATED WITH CONE PHOTORECEPTOR DEGENERATION | SORBONNE UNIVERSITE (FR) | 2026-05-13 | — | — | EP | claimed |
| US-12616691-B2 | Use of fatty acid oxidation inhibitors as antimicrobials | WASHINGTON UNIVERSITY IN ST. LOUIS (US) | 2026-05-05 | — | — | US | claimed |
| US-12616659-B2 | Therapeutic agent nanoparticles and methods of preparation | NANO PHARMASOLUTIONS, INC. (US) | 2026-05-05 | — | — | US | claimed |
| US-12582598-B2 | Topical anti-inflammatory pharmaceutical composition comprising Zileuton | QURIENT CO., LTD. (KR) | 2026-03-24 | — | — | US | claimed |
| EP-4696689-A1 | SALT FORM AND CRYSTAL FORM OF CHIRAL HETEROCYCLIC COMPOUND HAVING HEDGEHOG PATHWAY ANTAGONIST ACTIVITY | Suzhou Kintor Pharmaceuticals, Inc. (CN) | 2026-02-18 | — | — | EP | claimed |
| EP-4691470-A1 | USE OF HETEROCYCLIC COMPOUND IN TREATMENT OF INTERSTITIAL PNEUMONIA | SUZHOU KINTOR PHARMACEUTICALS, INC (CN) | 2026-02-11 | — | — | EP | claimed |
| US-12545948-B2 | Identification of novel loci in asthma and methods of use thereof for the diagnosis and treatment of asthma | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2026-02-10 | — | — | US | claimed |
| US-20260027337-A1 | TRANSDERMAL DRUG DELIVERY DEVICES AND METHODS | MORNINGSIDE VENTURE INVESTMENTS LTD (MC) | 2026-01-29 | — | — | US | claimed |
| EP-4683627-A1 | AMELIORATION OF DRUG-DRUG INTERACTIONS | Ontrack Therapeutics Limited (GB) | 2026-01-28 | — | — | EP | claimed |
| EP-0697868-A1 | METHODS AND COMPOSITIONS USING OPTICALLY PURE (+)-ZILEUTON | SEPRACOR, INC. (US) | 1996-02-28 | — | — | EP | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
| WO-1995024894-A9 | USE OF LIPOXYGENASE INHIBITORS AS ANTI-CANCER THERAPEUTIC AND INTERVENTION AGENTS | — | 1995-10-26 | — | — | WO | claimed |
| US-5461072-A | Use of aryl hydroxyurea compounds for the treatment of atherosclerosis | BURROUGHS WELLCOME CO. (US) | 1995-10-24 | — | — | US | claimed |
| WO-1995024894-A2 | USE OF LIPOXYGENASE INHIBITORS AS ANTI-CANCER THERAPEUTIC AND INTERVENTION AGENTS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-09-21 | — | — | WO | claimed |
| EP-0648488-A1 | Method to alter hairgrowth and compositions therefor | L'OREAL (FR) | 1995-04-19 | — | — | EP | claimed |
| WO-1994026268-A1 | METHODS AND COMPOSITIONS USING OPTICALLY PURE (+)-ZILEUTON | SEPRACOR, INC. (US) | 1994-11-24 | — | — | WO | claimed |
| WO-1994026269-A1 | METHODS AND COMPOSITIONS FOR TREATING ASTHMA, ATHEROSCLEROSIS ANDINFLAMMATORY DISEASES USING OPTICALLY PURE (-)-ZILEUTON | SEPRACOR, INC. (US) | 1994-11-24 | — | — | WO | claimed |
| EP-0543855-A1 | USE OF ARYL HYDROXYUREA COMPOUNDS FOR THE TREATMENT OF ATHEROSCLEROSIS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-06-02 | — | — | EP | claimed |
| WO-1992003130-A1 | USE OF ARYL HYDROXYUREA COMPOUNDS FOR THE TREATMENT OF ATHEROSCLEROSIS | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-03-05 | — | — | WO | claimed |